Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
Open Access
- 1 October 2023
- journal article
- research article
- Published by Wiley in HemaSphere
- Vol. 7 (10) , e961
Abstract
Myelodysplastic neoplasms (MDS) are a heterogeneous group of hematological stem cell disorders characterized by dysplasia, cytopenias, and increased risk of acute leukemia. As prognosis differs widely between patients, and treatment options vary from observation to allogeneic stem cell transplantation, accurate and precise disease risk prognostication is critical for decision making. With this aim, we retrieved registry data from MDS patients from 90 Spanish institutions. A total of 7202 patients were included, which were divided into a training (80%) and a test (20%) set. A machine learning technique (random survival forests) was used to model overall survival (OS) and leukemia-free survival (LFS). The optimal model was based on 8 variables (age, gender, hemoglobin, leukocyte count, platelet count, neutrophil percentage, bone marrow blast, and cytogenetic risk group). This model achieved high accuracy in predicting OS (c-indexes; 0.759 and 0.776) and LFS (c-indexes; 0.812 and 0.845). Importantly, the model was superior to the revised International Prognostic Scoring System (IPSS-R) and the age-adjusted IPSS-R. This difference persisted in different age ranges and in all evaluated disease subgroups. Finally, we validated our results in an external cohort, confirming the superiority of the Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS) over the IPSS-R, and achieving a similar performance as the molecular IPSS. In conclusion, the AIPSS-MDS score is a new prognostic model based exclusively on traditional clinical, hematological, and cytogenetic variables. AIPSS-MDS has a high prognostic accuracy in predicting survival in MDS patients, outperforming other well-established risk-scoring systems. ExportKeywords
This publication has 26 references indexed in Scilit:
- Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesBlood Advances, 2020
- Machine Learning in MedicineNew England Journal of Medicine, 2019
- Genetics of MDSBlood, 2019
- Future Promises and Concerns of Ubiquitous Next-Generation SequencingCold Spring Harbor Perspectives in Medicine, 2018
- Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS registerBritish Journal of Haematology, 2018
- Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryBritish Journal of Haematology, 2015
- The genetic basis of myelodysplasia and its clinical relevanceBlood, 2013
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromesAnnals of Oncology, 2009